Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim in TNBC Patients Receiving AC Regimen Following Paclitaxel/Carboplatin
NCT07525869Recruiting
- Sponsor
- Yonsei University
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegfilgrastim in triple-negative breast cancer (TNBC), sponsored by Yonsei University. Primary endpoint: Incidence of Febrile Neutropenia at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07525869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525869.